echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Two Aβ mAbs have been given priority review by the FDA. Can AD drugs turn the tide under the theoretical basis of the "Leaning Tower of Pisa"?

    Two Aβ mAbs have been given priority review by the FDA. Can AD drugs turn the tide under the theoretical basis of the "Leaning Tower of Pisa"?

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com




    According to statistics, there are 55 million dementia patients in the world, of which 60%-80% are dementia caused by AD


    Antibody drug group



    failed clinical trials



    ▲ Source of the results of two phase 3 trials of aducanumab: Bojian official website




    References:


    1.




    ——List of recent popular activities——


    ▼On August 14, the application and future prospects of TCR-T cell therapy in the treatment of solid tumors

    ▼August 16, mRNA preparation & LNP packaging whole process process points and quality control strategy


    ▼August 29, Phase 2: Immunometabolism Analysis, Helping Cellular Immunotherapy

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.